Jimandin

Sitagliptin, the active ingredient in Jimandin, is a Dipeptidyl peptidase‑4 (DPP‑4) inhibitor presented as an oral tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adult patients when diet, exercise, and other antidiabetic agents are insufficient to achieve glycaemic control.

GNH USA supplies Jimandin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for import and global distribution.

Sitagliptin is a DPP‑4 inhibitor used to improve glycaemic control in type 2 diabetes mellitus.

- Type 2 diabetes mellitus: improves glycaemic control by enhancing insulin secretion and reducing glucagon release in a glucose‑dependent manner.

Sitagliptin may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nasopharyngitis: mild inflammation of the upper airway. - Headache: transient mild to moderate pain. - Upper respiratory tract infection: symptoms of cough and congestion. - Nausea: occasional mild stomach upset. - Diarrhoea: loose stools that are usually self‑limiting.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain requiring immediate medical attention. - Severe hypersensitivity reactions: including rash, angioedema, or anaphylaxis. - Bullous pemphigoid: autoimmune blistering skin disorder. - Hepatic injury: elevated liver enzymes or hepatitis.

When prescribing sitagliptin, clinicians should consider several precautionary measures to ensure safe use.

- Renal function: assess renal impairment and adjust dose if necessary. - Hepatic impairment: monitor liver function in patients with existing liver disease. - Cardiovascular disease: use cautiously in patients with a history of heart failure. - Elderly patients: start at lower dose and monitor for hypoglycaemia when combined with insulin or sulfonylureas. - Pregnancy and lactation: safety not established; avoid use unless benefits outweigh risks. - Store below 25°C: keep in the original packaging, protect from moisture and light.

Sitagliptin can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Co‑administration with other DPP‑4 inhibitors: may increase risk of adverse effects without added benefit. - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase sitagliptin plasma concentrations.

Moderate Interactions (Monitor Closely): - Sulfonylureas or insulin: increased risk of hypoglycaemia; monitor glucose levels. - Diuretics (e.g., furosemide): may enhance risk of dehydration and renal impairment. - Rifampin: may reduce sitagliptin exposure; consider dose adjustment.